AnaptysBio (ANAB) Hits New 12-Month High at $111.42

AnaptysBio Inc (NASDAQ:ANAB) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $111.42 and last traded at $103.52, with a volume of 284100 shares. The stock had previously closed at $102.57.

Several research analysts recently commented on ANAB shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $35.00 target price on shares of AnaptysBio in a research report on Tuesday, September 12th. Zacks Investment Research raised AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Wednesday, September 13th. Royal Bank of Canada initiated coverage on AnaptysBio in a research report on Thursday, September 14th. They issued an “outperform” rating and a $40.00 target price for the company. JMP Securities lifted their price objective on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Finally, Credit Suisse Group lifted their price objective on AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $88.00.

The firm has a market capitalization of $2,530.00 and a price-to-earnings ratio of -68.56. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. equities research analysts anticipate that AnaptysBio Inc will post -1.72 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC acquired a new stake in shares of AnaptysBio in the third quarter valued at $20,406,000. Artal Group S.A. increased its stake in shares of AnaptysBio by 459.4% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after buying an additional 205,310 shares in the last quarter. VHCP Management II LLC acquired a new stake in shares of AnaptysBio in the third quarter valued at $5,856,000. JPMorgan Chase & Co. increased its stake in shares of AnaptysBio by 210.2% in the third quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock valued at $6,363,000 after buying an additional 124,219 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in shares of AnaptysBio in the third quarter valued at $2,796,000. 75.48% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “AnaptysBio (ANAB) Hits New 12-Month High at $111.42” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2018/01/10/anaptysbio-anab-hits-new-12-month-high-at-111-42.html.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit